Paul Friedrich Geus

Mr. Paul Friedrich Geus

Charité - Universitätsmedizin Berlin, Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
PGPaul Friedrich Geus
Paul Friedrich Geus
FHFelix Hehnen
Felix Hehnen
SKSophia Krakowski
Sophia Krakowski
KLKlaus Luecke
Klaus Luecke
DHDave Hoon
Dave Hoon
GWGabi Wendt
Gabi Wendt
Circulating tumor cells (CTCs) exist in low quantities in the bloodstream in the early stages of cancers. It, therefore, remains a technical challenge to isolate them in large enough quantities for a precise diagnosis and downstream analysis. We introduce the BMProbe™, a minimally invasive device that isolates CTCs during a 30-minute incubation in the median cubital vein. The optimized geometry of the device creates flow conditions for improved cell deposition. The CTCs are isolated using antibodies that are bound to the surface of the BMProbe™. In this study, flow experiments using cell culture cells were conducted. They indicate a 31 times greater cell binding efficiency of the BMProbe™ compared to a flat geometry. Further, the functionality of isolating CTCs from patient blood was verified in a small ex vivo study that compared the cell count from seven non-small-cell lung carcinoma (NSCLC) patients compared to nine healthy controls with 10 mL blood samples. The median cell count was 1 in NSCLC patients and 0 in healthy controls. In conclusion, the BMProbe™ is a promising method to isolate CTCs in large quantities directly from the venous bloodstream without removing blood from a patient. The future step is to verify the functionality in vivo.

26 July 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
SKSophia Krakowski
Sophia Krakowski
SCSara Campos
Sara Campos
HWHenri Wolff
Henri Wolff
GBGabi Bondzio
Gabi Bondzio
FHFelix Hehnen
Felix Hehnen
PGPaul Friedrich Geus
Paul Friedrich Geus
Background/Objectives: Liquid biopsy is a minimally invasive alternative to tissue biopsy and is used to obtain information about a disease from a blood sample or other body fluids. In the context of cancer, circulating tumor cells (CTC) can be used as biomarkers to determine the nature of the tumor, its stage of progression, and the efficiency of the administered therapy through monitoring. However, the low concentration of CTCs in blood (1–10 cells/mL) is a challenge for their isolation. Therefore, a minimally invasive medical device (BMProbe™) was developed that isolates CTCs via antigen–antibody binding directly from the bloodstream. Current investigations focus on the process of detaching bound cells from the BMProbe™ surface for cell cultivation and subsequent drug testing to enable personalized therapy planning. Methods: This article presents two approaches for detaching LNCaP cells from anti-EpCAM coated BMProbes™: enzymatic detachment using TrypLE™ and detachment through enzymatic pretreatment with supplementary flow-induced shear stress. The additional shear stress is intended to increase the detachment efficiency. To determine the flow rate required to gently detach the cells, a computational fluid dynamics (CFD) simulation was carried out. Results: The experimental test results demonstrate that 91% of the bound cells can be detached enzymatically within 10 min. Based on the simulation, a maximum flow rate of 47.76 mL/min was defined in the flow detachment system, causing an average shear stress of 8.4 Pa at the probe edges. The additional flow treatment did not increase the CTC detachment efficiency. Conclusions: It is feasible that the detachment efficiency can be further increased by a longer enzymatic incubation time or higher shear stress. The influence on the integrity and viability of cells must, however, be considered.

11 December 2024
Verified
Conference Paper
Closed access
SBSophie Becke
Sophie Becke
PGPaul Friedrich Geus
Paul Friedrich Geus
GBGabi Bondzio
Gabi Bondzio
JSJan Schroer
Jan Schroer
VFVera Froese
Vera Froese
MLMichael Lommel
Michael Lommel
Respiratory tract infections (RTIs), including COVID-19, influenza, and respiratory syncytial virus infections represent a significant global health burden. Traditional diagnostic methods, such as polymerase chain reaction (PCR) and rapid antigen tests, have limitations in terms of invasiveness, time consumption, and sensitivity. To address these challenges, we developed a gold nanoparticle-based breath test device that enables rapid, non-invasive detection of infections at the point-of-care (POC). The device measures the colorimetric properties of gold nanoparticles (GNPs), which change upon aggregation when exposed to specific antigens filtered from exhaled breath. The system integrates sampling and analysis in a portable unit, providing results within 30 seconds. In this proof-of-concept, we demonstrate the detection of SARS-CoV-2 antigens through shifts in the localized surface plasmon resonance (LSPR) of GNPs. Initial tests using NaCl-induced GNP aggregation validate the device's functionality. This innovative approach shows promising first results for rapid, user-friendly infection diagnostics from exhaled breath, with potential applications in mass screening and POC testing. Further optimization is needed to enhance sensitivity and reliability

16 November 2026 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PGPaul Friedrich Geus
Paul Friedrich Geus
TBTim Bierewirtz
Tim Bierewirtz
FHFelix Hehnen
Felix Hehnen
SHSusan Henniger
Susan Henniger
UKUlrich Kertzscher
Ulrich Kertzscher
MLMichael Lommel
Michael Lommel
Background: Intravitreal injections are the most frequently performed intraocular procedure worldwide. Yet the 50 µL dose is usually delivered with syringes designed neither for volumes this small nor for injection into the eye. Dosing accuracy, particulate contamination and residual volume have previously been examined in separate studies, so trade-offs between these properties within a single syringe remain unclear. We assessed all three properties in the same syringes, including models in clinical use for intravitreal injection that have not been characterised previously. Methods: Six syringes were evaluated: Injekt ® -F Luer Solo 1 mL, Omnifix-F Luer Lock Solo 1 mL, Henke-Ject eco 1 mL (three-part), Zero Residual 0.2 mL, BD Micro-Fine 1 mL, and Omnican 50 U-100 insulin syringe. Dosing accuracy and precision for a 50 µL target volume was assessed with 23 specialist staff. The dosing data were analysed descriptively, and operator-dependent variability was quantified with a linear mixed model. Residual volume was determined according to DIN EN ISO 7886-1. Particulate contamination was quantified by light obscuration after 7-day incubation of water, with and without flicking of the syringe during filling. Particle counts were analyzed descriptively. Results: All syringes tended to overdose, with a median delivered volume of 55.1 µL, and only 45.4% of the measurements were within 45–55 µL. In the mixed model, 22% of the variance of the delivered volume was attributable to between-operator differences, and no syringe type differed significantly in mean delivered volume. Among the syringes measured without a needle, the mean residual volume ranged from 0.18 µL to 23.1 µL; the two syringes with integrated needles showed 0.59 µL and 1.77 µL including the needle dead space. All syringes released particulate matter, and in this exploratory study the particle count was higher after flicking in five of the six syringe types. Conclusions: None of the evaluated syringes performed optimally across all properties assessed. The Zero Residual 0.2 mL showed the lowest residual volume of the syringes measured without a needle and low particle concentrations without flicking, but delivered individual doses well outside the target range and showed a ten-fold rise in particle concentration after flicking. Repurposed syringes delivered volumes of up to 98 µL.